Longitudinal Evaluation of Antibody Kinetics of Vaccinated Patients With Non-mandatory Vaccine Following Administration of a Non-public Marketed Vaccine in the General Population, Real-life Study

Longitudinal Evaluation of Antibody Kinetics Following Administration of a Non-mandatory Marketed Vaccine in the General Population, Real-life Study

Status

Not yet recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06373510

Acronym

ELCAV

Enrollment

10000

Registered

2024-04-18

Start date

2024-06-20

Completion date

2027-04-03

Last updated

2024-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaccination Reaction

Brief summary

The study would make it possible to document more explicitly the evolution of antibody titers at following a non-public vaccination over a large post-vaccination period in the French population . Analysis of real-life data would enhance knowledge of vaccine response kinetics It would be useful to identify possible early declines requiring doses Similarly, by analyzing antibody kinetics by age, sex, and vaccination status, the would be possible to determine whether there are differences in the immune response between these different sub-groups. In addition, it would provide additional information to assess the real impact of these non-public vaccines in public health and guide vaccine policies.

Interventions

BIOLOGICALBlood collection

Collection of blood before and after a non mandatory vaccination

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Yes

Inclusion criteria

* Subject over 18 years of age * Subject presenting to the investigation centre as part of its usual management (prevention, screening, tracking) * Subject who has been vaccinated and/or wishes to be vaccinated * Subject able to understand the purpose of research that has given free and informed express consent * Member or beneficiary of a social security scheme

Exclusion criteria

* Protected subject: major under guardianship, curatorship or other legal protection, deprived of liberty by decision judicial or administrative

Design outcomes

Primary

Measure	Time frame	Description
Quantification of specific serum antibodies (IgM, IgG) at different times before and/or after vaccination by a reference technique such as ELISA.	3 years	Quantification of specific serum antibodies (IgM, IgG) at different times before and/or after vaccination by a reference technique such as ELISA.

Contacts

Primary ContactBarbara Perniconi

bperniconi@cerbaresearch.com0671296728

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026